Intensive diabetes treatment reduces retinopathy risk

Article

Patients with type 1 diabetes who have been treated with intensive therapy have significantly lower incidences of retinopathy progression up to ten years, according to study results published in the December issue of the Archives of Ophthalmology.

Patients with type 1 diabetes who have been treated with intensive therapy have significantly lower incidences of retinopathy progression up to ten years, according to study results published in the December issue of the Archives of Ophthalmology.

The Epidemiology of Diabetes Interventions and Complications (EDIC) Research Group assessed patients who had been enrolled in the Diabetes Control and Complications Trial (DCCT), which concluded in 1993. Patients in the DCCT were treated with intensive therapy to lower the risk of microvascular diabetic complications when compared with standard therapy. At the four-year follow-up point, patients in the intensive treatment arm had a 70–71% reduced risk of microvascular complications when compared with patients in the conventional treatment study arm.

At year 10 of the EDIC follow-up study, the researchers used fundus photography to assess retinopathy in 1211 subjects. Patients had similar levels of glycated haemoglobin regardless of their initial treatment (standard or intensive), although patients treated intensively had significantly fewer instances of either progression of retinopathy or development of proliferative retinopathy, or worse, after the final DCCT follow-up visit when compared with subjects treated conventionally. The risk reductions experienced by the intensively-treated patients attenuated over the 10-year course of the EDIC trial.

Thus the EDIC Research Group concluded that, though the effects appear to decrease over time, intensive therapy for type 1 diabetes lowers the risk of retinopathy progression.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Related Content
© 2025 MJH Life Sciences

All rights reserved.